-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $85

Benzinga·06/15/2026 17:26:27
Listen to the news
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $70 to $85.